Association between BDNF Val66Met polymorphism and mild behavioral impairment in patients with Parkinson’s patients
Objective: This study investigates if PD patients with Brain-derived-neurotrophic-factor (BNDF) Met allele are more likely to have Mild behavioral impairment (MBI). And whether Met allele…The Personalized Parkinson Project – data quality enhancing strategies
Objective: Demonstrate the impact of quality enhancing strategies in the Personalized Parkinson Project. Background: Increasingly, the scientific community uses data from longitudinal observational patient cohorts…AADC gene therapy administered via a posterior approach: 18-month results from the PD-1102 trial in advanced Parkinson’s disease
Objective: To report 18-month safety and clinical outcomes from a phase 1, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor fluctuations.…Comparison of Categorical- and Verbatim-Reported Postural Instability Symptoms Among Fox Insight Parkinson Research Participants
Objective: To analyze verbatim patient-reported problems compared with ordinal measures referable to Postural Instability (PI) symptoms in the Fox Insight (FI) observational study. Background: FI…Prospective assessment of the lessebo effect in placebo-controlled randomized trials using an expectancy questionnaire
Objective: To prospectively measure the lessebo effect using an expectancy questionnaire (EQ). Background: The presence of a placebo arm in a randomized controlled trial has…Therapeutic Benefits of Music for Three Types of Neurological Disorders: an fNIRS Study Protocol for Controlled Trial in Dalian, China, Part 1-Parkinson’s Disease
Objective: It is investigated that the external auditory stimuli affect motor synchronization and control in patients with PD,and further studied that how music therapy or other…Improving automaticity of walking in Parkinson’s disease: Levodopa or Donepezil?
Objective: Determine whether levodopa replacement or cholinergic augmentation improve automaticity of walking in people with Parkinson’s disease (PD). Background: Degradation of dopaminergic striatal mechanisms of…Using a Delphi process to inform the design of disease modifying trials in Parkinson’s disease
Objective: To consolidate current opinion on trial methodology of disease modifying therapies (DMTs) for Parkinson’s disease (PD) and establish consensus on a core protocol for…Levodopa and dopamine agonists dosage changes after Opicapone introduction
Objective: We aim to analyze changes in levodopa and dopamine agonists (DA) dosage after introduction of opicapone (OPC) in a daily clinical practice setting. Background:…Maintenance of safinamide 100 mg daily long-term
Objective: Evaluating the maintenance of safinamide 100 mg daily as a long-term treatment Background: The effects of safinamide were investigated in studies 016, 018 and…
- « Previous Page
- 1
- …
- 126
- 127
- 128
- 129
- 130
- …
- 149
- Next Page »